PL358205A1 - Pochodne 8-chinolinoksantyny i 8-izochinolinoksantyny jako inhibitory PDE5 - Google Patents
Pochodne 8-chinolinoksantyny i 8-izochinolinoksantyny jako inhibitory PDE5Info
- Publication number
- PL358205A1 PL358205A1 PL01358205A PL35820501A PL358205A1 PL 358205 A1 PL358205 A1 PL 358205A1 PL 01358205 A PL01358205 A PL 01358205A PL 35820501 A PL35820501 A PL 35820501A PL 358205 A1 PL358205 A1 PL 358205A1
- Authority
- PL
- Poland
- Prior art keywords
- quinolinxanthine
- isoquinolinxanthine
- pde
- inhibitors
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0008694.2A GB0008694D0 (en) | 2000-04-07 | 2000-04-07 | Organic compounds |
PCT/EP2001/003909 WO2001077110A1 (en) | 2000-04-07 | 2001-04-05 | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
PL358205A1 true PL358205A1 (pl) | 2004-08-09 |
PL212407B1 PL212407B1 (pl) | 2012-09-28 |
Family
ID=9889516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL358205A PL212407B1 (pl) | 2000-04-07 | 2001-04-05 | Zwiazek pochodny 8-chinolinoksantyny i 8-izochinolinoksantyny, jego zastosowanie, kompozycja farmaceutyczna zawierajaca zwiazek oraz sposób wytwarzania zwiazku |
Country Status (29)
Country | Link |
---|---|
US (1) | US20030171384A1 (pl) |
EP (1) | EP1268480B1 (pl) |
JP (1) | JP3869725B2 (pl) |
KR (1) | KR100526094B1 (pl) |
CN (1) | CN1176922C (pl) |
AR (1) | AR028531A1 (pl) |
AT (1) | ATE253576T1 (pl) |
AU (2) | AU7392101A (pl) |
BR (1) | BR0109855A (pl) |
CA (1) | CA2403514C (pl) |
CZ (1) | CZ20023305A3 (pl) |
DE (1) | DE60101158T2 (pl) |
DK (1) | DK1268480T3 (pl) |
ES (1) | ES2210169T3 (pl) |
GB (1) | GB0008694D0 (pl) |
HU (1) | HUP0300565A3 (pl) |
IL (1) | IL152078A0 (pl) |
MX (1) | MXPA02009903A (pl) |
MY (1) | MY119238A (pl) |
NO (1) | NO20024741D0 (pl) |
NZ (1) | NZ521361A (pl) |
PE (1) | PE20020228A1 (pl) |
PL (1) | PL212407B1 (pl) |
PT (1) | PT1268480E (pl) |
RU (1) | RU2269529C2 (pl) |
SK (1) | SK14282002A3 (pl) |
TR (1) | TR200400185T4 (pl) |
WO (1) | WO2001077110A1 (pl) |
ZA (1) | ZA200207956B (pl) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
US7019010B2 (en) * | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
DE60327628D1 (de) * | 2002-06-12 | 2009-06-25 | Hoffmann La Roche | Amid substituierte xanthin derivate mit gluconeogenesis modulierender wirkung |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP4233524B2 (ja) * | 2002-08-21 | 2009-03-04 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 8−[3−アミノ−ピペリジン−1−イル]−キサンチン、その製造およびその薬理組成物としての使用 |
US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
ES2298722T3 (es) * | 2003-02-19 | 2008-05-16 | F. Hoffmann-La Roche Ag | Derivados de xantina sustituida con sulfonamida para el uso como inhibidores de fosfoenolpiruvatocarboxicinasa (pepck). |
US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
KR100658080B1 (ko) * | 2003-08-26 | 2006-12-15 | 비오이 하이디스 테크놀로지 주식회사 | 백라이트 조립용 지그 |
TW200605893A (en) * | 2004-02-12 | 2006-02-16 | Novartis Ag | Use of organic compounds |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
WO2005110991A1 (en) * | 2004-05-08 | 2005-11-24 | Neurogen Corporation | 1-aryl-4-substituted isoquinolines |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005001989A1 (de) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenöse Formulierungen von PDE-Inhibitoren |
US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
KR20100029762A (ko) * | 2007-06-13 | 2010-03-17 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 청력 장애 치료용 pde 억제제 |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US8513264B2 (en) | 2008-09-10 | 2013-08-20 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
US8841447B2 (en) * | 2009-03-26 | 2014-09-23 | Mapi Pharma Ltd. | Process for the preparation of alogliptin |
KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
RU2013142364A (ru) * | 2011-02-18 | 2015-03-27 | Аллерган, Инк. | Замещенные производные 6,7-диалкокси-3-изохинолинола в качестве ингибиторов фосфодиэстеразы 10 (фдэ10а) |
US8962636B2 (en) | 2011-07-15 | 2015-02-24 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2014071044A1 (en) * | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2558162B1 (fr) * | 1984-01-17 | 1986-04-25 | Adir | Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
AU4501199A (en) * | 1998-06-03 | 1999-12-20 | Almirall Prodesfarma S.A. | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors |
GB9828340D0 (en) * | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
-
2000
- 2000-04-07 GB GBGB0008694.2A patent/GB0008694D0/en not_active Ceased
-
2001
- 2001-04-05 US US10/240,481 patent/US20030171384A1/en not_active Abandoned
- 2001-04-05 NZ NZ521361A patent/NZ521361A/en unknown
- 2001-04-05 BR BR0109855-1A patent/BR0109855A/pt not_active IP Right Cessation
- 2001-04-05 WO PCT/EP2001/003909 patent/WO2001077110A1/en active IP Right Grant
- 2001-04-05 HU HU0300565A patent/HUP0300565A3/hu unknown
- 2001-04-05 SK SK1428-2002A patent/SK14282002A3/sk unknown
- 2001-04-05 AU AU7392101A patent/AU7392101A/xx active Pending
- 2001-04-05 KR KR10-2002-7012627A patent/KR100526094B1/ko not_active IP Right Cessation
- 2001-04-05 DK DK01940294T patent/DK1268480T3/da active
- 2001-04-05 IL IL15207801A patent/IL152078A0/xx unknown
- 2001-04-05 DE DE60101158T patent/DE60101158T2/de not_active Expired - Lifetime
- 2001-04-05 CA CA002403514A patent/CA2403514C/en not_active Expired - Fee Related
- 2001-04-05 EP EP01940294A patent/EP1268480B1/en not_active Expired - Lifetime
- 2001-04-05 PT PT01940294T patent/PT1268480E/pt unknown
- 2001-04-05 PL PL358205A patent/PL212407B1/pl unknown
- 2001-04-05 JP JP2001575583A patent/JP3869725B2/ja not_active Expired - Fee Related
- 2001-04-05 ES ES01940294T patent/ES2210169T3/es not_active Expired - Lifetime
- 2001-04-05 MY MYPI20011632A patent/MY119238A/en unknown
- 2001-04-05 MX MXPA02009903A patent/MXPA02009903A/es active IP Right Grant
- 2001-04-05 RU RU2002129557/04A patent/RU2269529C2/ru not_active IP Right Cessation
- 2001-04-05 CZ CZ20023305A patent/CZ20023305A3/cs unknown
- 2001-04-05 PE PE2001000317A patent/PE20020228A1/es not_active Application Discontinuation
- 2001-04-05 AT AT01940294T patent/ATE253576T1/de active
- 2001-04-05 TR TR2004/00185T patent/TR200400185T4/xx unknown
- 2001-04-05 CN CNB018074898A patent/CN1176922C/zh not_active Expired - Fee Related
- 2001-04-05 AU AU2001273921A patent/AU2001273921B2/en not_active Ceased
- 2001-04-05 AR ARP010101623A patent/AR028531A1/es not_active Application Discontinuation
-
2002
- 2002-10-02 NO NO20024741A patent/NO20024741D0/no not_active Application Discontinuation
- 2002-10-03 ZA ZA200207956A patent/ZA200207956B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7392101A (en) | 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors | |
AU2001244355A1 (en) | Heterobiarylsulphonamides and their use as pde 7 inhibitors | |
SI1686119T1 (sl) | Derivati pirimidin-5-ona kot inhibitorji ldl-pla2 | |
HUP0302412A3 (en) | Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same | |
IL153246A0 (en) | Substituted quinazoline derivatives and their use as inhibitors | |
IL151919A0 (en) | Imidazopyridine derivatives and triazolpyrimidine derivatives | |
HK1061851A1 (en) | Gyrase inhibitors and uses thereof | |
AU2001240542A1 (en) | Heterocyclic compounds and their use as parp inhibitors | |
HK1061854A1 (en) | Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
EP1383743A4 (en) | DOUBLE INHIBITORS OF PDE 7 AND PDE 4 | |
SI1251848T1 (en) | Gyrase inhibitors and uses thereof | |
GB0025782D0 (en) | Use of inhibitors | |
AU6117801A (en) | Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors | |
HK1053107A1 (zh) | 作為jnk抗化劑的pyrazoloanthrone及其衍生物和它們的成份 | |
IL151614A0 (en) | Apomorphine derivatives and methods for their use | |
AU8323701A (en) | Inhibitors of p38 | |
HUP0400654A3 (en) | Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them | |
HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them | |
PL361733A1 (pl) | Sulfamidotienopirymidyny | |
AU2001276027A1 (en) | Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors | |
AU2002216650A1 (en) | Triazine derivatives as lpaat-b inhibitors and uses thereof | |
AU2002241211A1 (en) | Imidazo-triazine derivatives as pde 5 inhibitors | |
IL152792A0 (en) | Heterocycle derivatives and methods of use | |
HRP20020970A2 (en) | 2-aminothiazoline derivatives and their use as no-synthase inhibitors | |
AU4834101A (en) | N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them |